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Research indicates that certain antihypertensive medications alter Alzheimer’s disease (AD) biomarkers 
in Caucasians. The renin angiotensin system (RAS) regulates blood pressure (BP) in the body and the 
brain and may directly influence AD biomarkers, including Aβ neuropathology, cerebral blood flow 
(CBF) and inflammatory markers. This hypothesis is supported by studies, including ours, showing that 
antihypertensives targeting the RAS reduce the risk and slow the progression of AD in Caucasians. 
While mounting evidence supports a protective role of RAS medications in Caucasians, this mechanism 
has not been explored in African Americans. 
To assess the mechanism by which RAS medications modify the brain RAS, CSF Aβ, CBF, and 
inflammatory markers in African Americans, we are conducting an eight month, Phase Ib randomized, 
placebo controlled trial, enrolling 60 middle-aged (45–70yrs), non-demented individuals, at risk for AD 
by virtue of a parental history. 
Participants include normotensive and treated hypertensives that have never been exposed to a RAS 
medication. Participants are randomized (1:1:1) by gender and BP medication use (yes/no)to one of three 
groups: placebo, or 20mg, or 40mg telmisartan (Micardis), to determine the dose required to penetrate the 
CNS. Our overarching hypothesis is that, compared to placebo, both doses of telmisartan will penetrate 
the CNS and produce salutary, dose dependent effects on the brain RAS as well as CSF Aβ, CBF and 
CSF inflammatory markers in African Americans, over eight months. This manuscript describes the  trial 








Certain antihypertensive medications appear to alter Alzheimer’s disease (AD) biomarkers in 
Caucasians and African Americans [1, 2]. The renin angiotensin system (RAS) regulates blood 
pressure (BP) and fluid maintenance in the body and the brain, and may directly influence AD 
biomarkers, including Aβ and tau, cerebral blood flow (CBF) and inflammatory markers [3-5]. 
This hypothesis is supported by studies showing that antihypertensives targeting the RAS, that 
most commonly are angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II 
receptor blockers (A2RBs), reduce the risk and slow the progression of clinical AD [6-8]. We 
have shown that 1) blood brain barrier (BBB) crossing RAS medications exert protective 
cognitive effects and slow disease progression in hypertensive individuals with MCI, and 2) 
BBB crossing RAS medications are able to significantly alter brain RAS levels in middle aged 
Caucasians at risk for AD due to a parental history [9].  
While mounting evidence supports a protective role of RAS medications in Caucasians, this 
mechanism has not been clinically tested in African Americans. We recently published a meta-
analysis that reported the rate of AD incidence is 64% higher for African Americans than for 
Caucasians [10]. Moreover, we estimated the current U.S. AD prevalence for ages 65–90 to be 
5.5% for Caucasians, and 8.6% for African Americans (prevalence ratio 1.56). Thus, not only are 
African Americans more likely to become afflicted with AD, they are also living longer with the 
disease. Because African Americans are at higher risk for AD than Caucasians, and RAS 
medications have shown to positively influence AD biomarkers and clinical disease progression, 
the potential benefit of RAS acting medications in this high risk population needs to be 
addressed.  
  
 African Americans are at higher risk for vascular risk factors, including hypertension, which 
independently contributes to cognitive impairment and AD, possibly via RAS regulation [11]. 
African Americans have lower circulating renin and higher aldosterone and sodium levels than 
Caucasians, and therefore RAS antihypertensives, which are those medications believed to exert 
AD-related benefits in Caucasians, are not indicated for African Americans, though safety and 
efficacy studies of RAS acting medications show that they are well tolerated [12, 13].  If RAS 
medications are prescribed, higher doses are generally required to achieve comparable BP 
control to that seen in Caucasians at lower doses. Importantly, the dose needed to alter RAS 
levels in the brain is unknown, and may be lower than the dose required to alter BP, as suggested 
by observed benefits of an ARB on cognitive decline that were independent of changes in BP. 
While many researchers now argue that prescription practices based on race are unwarranted, 
these trends persist in clinical practice and were upheld in the JAMA Guidelines for the 
treatment of hypertension in 2014 [14]. Because we know that the brain RAS is implicated in 
AD neuropathology and we can manipulate this system in the brains of Caucasians [15], we are 
investigating whether RAS medications confer similar AD-related benefits in African 
Americans, and whether we can clinically alter this system, and at what dose.  
We previously reported that individuals taking RAS acting medications (ACE-Is or A2RBs), 
particularly those that are centrally acting, show slower cognitive decline and are less likely to 
progress from MCI to AD over three years [16].  However, the potential mechanism was unclear 
due to the absence of neuropathological findings, although results are consistent with studies of 
post-mortem brain tissue of AD patients, that point to elevations of angiotensin converting 
enzyme (ACE), that both ACE-Is and A2RBs are designed to mitigate [17]. More recently, we 
confirmed these results, and further reported that individuals taking RAS acting medications 
  
exhibited significantly fewer neurofibrillary tangles (NFT) than non-RAS users in 5 brain 
regions including the mid-frontal cortex, mid-temporal cortex, inferior parietal cortex, entorhinal 
cortex, and hippocampal CA1 region manuscript under review.).  
Importantly, because Aβ and tau accumulation and RAS dysfunction begin during midlife, it is 
imperative to investigate these biomarkers in middle-aged, presymptomatic adults, while there is 
time to intervene, before the irreversible AD cascade begins. Further, exploring the potential 
benefit of using existing drugs (i.e. “repurposing”) that are generally recognized as safe, such as 
RAS medications, shortens the time needed to demonstrate efficacy, and thus, more rapidly 
provides urgently needed treatment options for this devastating illness.   
Here we describe the rationale and design of the ‘Mechanistic Potential of Antihypertensives in 
Preclinical Alzheimer's Trial,’ (HEART). This trial is funded by the Alzheimer’s Association 
Program Part the Cloud Translational Research Funding for Alzheimer's Disease Grant (PCTR) 
mechanism (PI: Wharton). The trial, which is coordinated at Emory University, began in March 
2015. HEART is a Phase Ib double blind, randomized, placebo-controlled trial to determine 
whether RAS medications modify the brain RAS, CSF Aβ and tau, cerebral blood flow (CBF) as 
well as central and peripheral inflammatory markers. This trial will recruit 66 middle-aged (45-
65 yrs), non-demented African Americans who have a parental history of AD. Participants 
include normotensives and untreated and treated hypertensives. Participants are randomized by 
gender and antihypertensive use (y/n) to one of three groups: placebo, 20mg telmisartan, or 
40mg telmisartan. Our overarching hypothesis is that, compared to placebo, both doses of 
telmisartan will penetrate the CNS and produce salutary, dose dependent effects on the brain 




Participants: Sixty-six non-Hispanic African American participants will be enrolled to achieve a 
final N = 60 assuming a 10% drop out rate over the 8 month trial. Both normotensive and 
hypertensive individuals are allowed to participate. Recruitment methods include the 1) Emory 
ADRC; 2) Emory Cognitive Neurology Clinics; 3) community based recruitment (churches, 
health fairs etc.); and 4) E-mail blasts to existing Emory research cohorts. Inclusion and 
exclusion criteria are outlined below. Parental history is confirmed by either autopsy-
confirmation or probable AD as defined by NINDS-ADRDA criteria [18], if the participant’s 
parent was seen at an ADRC or the Emory Memory Clinic. Parental diagnosis is further verified 
using the validated Dementia Questionnaire and medical records, when available [19]. While 
subjective memory complaints, AD medications and MOCA score are all used in an attempt to 
exclude individuals with MCI, lack of a clinical diagnosis and medical records for these 
participants is a limitation of the study.  
 
Inclusion Criteria (i) a biological parent with or who had AD; (ii) African American (iii) ≥ 45 
years of age; (iv) willing to fast for eight hours (v); willingness to undergo all procedures 
including blood draw, lumbar puncture (LP) and MRI (vi) willingness to take a study medication 
daily for 8 months. 
 
Exclusion Criteria (i) Current or past (past 10 yrs) use of a RAS acting medication; (ii) 
contraindication for LP or MRI; (iii) significant neurologic disease; (iv) heart failure; (v) type I 
or II diabetes; (vi) history of significant head trauma; (vii) major depression within the past two 
  
years; (viii) HIV / AIDS;  (ix) history of alcohol or substance abuse; (x) significant systemic 
illness or unstable medical condition that could affect cognition or cause difficulty complying 
with or completing the protocol; (xi) diagnosis of AD; (xii), subjective cognitive impairment 
MCI or residence in a skilled nursing facility; (xiii) use of another investigational medication or 
AD medication; (xiv) unwillingness to fast. 
 
Study Medication Rationale: 
The primary goal of this Phase Ib trial is to assess 1) the central activation and 2) the influence 
on AD biomarkers, by low and clinical starting doses of an FDA-approved RAS-acting 
medication. Participants taking a RAS medication currently or within the past 10 years (ACE-I 
or ARB) are not eligible for enrollment. The clinical starting dose of telmisartan for BP control 
in Caucasians is 40 mg. This study will test the central activation of the drug at 20 mg vs 40 mg 
vs placebo in African Americans, since they are commonly given higher RAS-acting medication 
doses to achieve BP control. Importantly, though African Americans are given higher doses for 
BP control, the dose required to cross the BBB and alter the brain RAS is unknown, and it is 
likely that this dose is lower than the dose required to alter BP in the body.  
 
Intervention and randomization: Standardized randomization by the study biostatistician is used 
to assign participants by gender and antihypertensive use (y/n) by the Emory Pharmaceutical 
Research Center to receive 20 mg telmisartan (N = 22), or 40 mg telmisartan (N = 22) or placebo 
(N = 22) to be taken once daily before bed. We chose to randomize by gender based on past 
studies enrolling African Americans, where we have an overrepresentation of women 
participants vs. men. Yes/no was selected as the randomization classification for non RAS-acting 
  
medication use because the central question is RAS use vs placebo, thus we are not randomizing 
by medications that act via different mechanisms. Study drug and placebo are formulated into 
identical capsules. The PI, study personnel and participants are blind to drug assignment. A study 
physician ensures BP control and is the only individual aware of drug assignment. The purpose 
of this Phase I RTC is not to control BP; therefore, we do not assume control of the participants’ 
BP maintenance as long as they are within safe limits. All participants remain on their 
medications as prescribed by their primary care physician (PCP) in addition to taking the study 
medication or placebo pill. All participants’ PCPs are sent a letter describing the HEART project 
at Baseline. Participants whose BP is too high or low at screening, or whose BP drops to unsafe 
levels during the study are referred to their PCP. In addition to the study medication (telmisartan 
or placebo), other non-RAS acting medications (e.g. HCTZ, calcium channel blockers and beta 
blockers) are allowed. Once participants are enrolled, addition of RAS-acting antihypertensive 
medications is not allowed. Medication compliance is assessed using pill count at Month 4 and 
Month 8.  
 
Trial Description Summary: 
Figure 1 shows the timeline and visit procedures of the HEART trial (NCT02471833). Details of 
each visit and procedures are also described below.  Participants attend between 5-7 visits over 
the course of the 8 month trial depending on the number of safety visits needed. An initial phone 
interview determines eligibility and introduces the study protocol using standardized questions. 
Those who are eligible are invited for a screening visit, which takes approximately one hour. If 
blood levels assessing kidney and liver function, blood cell count, (potassium and creatinine) and 
BP values are within range (outlined below), individuals are asked to return for a Baseline visit 
  
and randomization. Prior to the Baseline visit, each participant’s primary care physician is 
mailed a letter outlining the HEART trial. Baseline visits are fasting, take approximately 6 hours, 
and can take place on one day or split between 2 days. Participants begin taking the study drug 
after all Baseline procedures are complete. Participants are then seen after 2-weeks for a safety 
visit, which lasts approximately 30 minutes. If all blood levels and BP values are within range 
(See screen visit description below), participants return at Month 4. In the event that a blood 
measure or BP value is out of range, participants are advised to visit their PCP and asked to 
return for a second safety visit, and again referred to their PCP if out of range values persist and 
scheduled for a 3rd safety visit. If BP or blood measures remain out of range after the 3rd safety 
visit, the participant would not be permitted to continue with the trial. Participants return at 
Month 4 for drug refill, pill count, BP reads and blood draw, which takes one hour. At Month 8, 
participants return for their final fasting 6-hour visit, which is identical to Baseline, except drug 
is not dispensed.  
 
Study Visit Specifics: 
Screening: Initial eligibility is determined via phone interview by a member of the HEART team, 
at which time a screening questionnaire and the Dementia Questionnaire are administered [19]. 
This screening process explores a potential participant’s match against the inclusion and 
exclusion criteria described above, and eligible individuals are invited for a clinic-based face-to-
face screening visit. The in-person screening visit includes obtaining informed consent, 
collecting medical and medication information, a cognitive screening questionnaire [20] two 
seated BP measurements, and a metabolic safety panel for hyperkalemia and renal insufficiency. 
Participants are unable to proceed to Baseline for the following: potassium > 5.0 mg/dL or 
  
creatinine > 1.99 mg/dL and / or systolic BP < 110 mm/Hg or >170 mm/Hg, or MOCA score < 
26. Eligible participants are asked to return for randomization and a Baseline visit within 30 days 
 
Baseline, and Randomization: During this visit, BP, blood cell count (BCC), neuropsychological 
testing, physical exam, blood draw, MRI, LP and vascular ultrasound are completed. Participants 
are randomized by PRC and begin study medication (or placebo) after this visit.  
 
Safety (Week 2) Visits: Following Baseline, participants are seen at Week 2 for BP assessment, 
metabolic blood panel, heart rate, symptom checklist, adverse events questionnaire (AE), and 
health history and medication history update. While potassium and creatinine cut-off criteria are 
the same as Screening, systolic BP at Safety and Month 4 visits must be ≥ 90 mm/Hg. If all 
measures are within range, the participant returns at Month 4. If BP or blood levels are not 
within limits, the participant is advised to schedule a visit with their PCP for treatment. The 
participants are then asked to return in 2 weeks for another safety visit. If a participant’s BP or 
blood levels do not improve by three Safety Visits, they would still be able to continue in the 
trial, but they are not allowed to continue on study drug.  
 
Month 4 Visit: This midpoint visit lasts one hour and includes pill count and medication 
dispensing, AE questionnaire and symptom checklist, blood draw, and BP measures.  
 
Month 8 / Study Completion: The final six hour visit includes: BP, AE questionnaire, symptom 
checklist, pill count, neuropsychological testing, neuroimaging, vascular ultrasound, LP and 
  
blood collection. This is a fasting visit and is identical to the Baseline visit except for medication 
dispensing.  
 
Procedure Descriptions:  
Arterial Function Assessment via Ultrasound – PWV: Pulse wave velocity (PWV) is non-
invasive and is administered at Baseline and Month 8. This is a measure of arterial stiffness, 
which has been shown to be superior to clinical BP measures when predicting cognitive decline 
in healthy populations and may be more sensitive to BP medication changes than other measures 
[21]. PWV is a highly reproducible measure of artery wall stiffness and is strongly correlated 
with cardiovascular events and all-cause mortality. Both PWV and PWA are assessed using 
measurements of the radial, carotid, and femoral arteries, using the SphygmoCor Pulse Wave 
Velocity system (PWV Medical). In brief, peripheral pressure waveforms were recorded from 
the radial artery at the wrist, using applanation tonometry with a high-fidelity micromanometer. 
After 20 sequential waveforms are acquired, a validated generalized transfer function is used to 
generate the corresponding central aortic pressure waveform, and the degree of pressure 
augmentation due to the reflected wave form from the periphery is measured. Central AIx is 
calculated as the augmented pressure divided by the central pulse pressure from the central 
pressure waveform. Carotid-femoral artery PWV is determined by measuring transcutaneous 
Doppler flow velocity recordings carried out over the common carotid artery and the femoral 
artery.  
 
Ambulatory Blood Pressure Monitoring  
  
Ambulatory BP is assessed at Baseline and Month 8 and endpoints include 1) mean 24 hour 
ambulatory BP and 2) nocturnal dipping percentage defined as:   Ambulatory 
BP monitors (model 90207-1Q) from Spacelabs Healthcare© are calibrated monthly. Blood 
pressure is measured every twenty minutes while the participant is awake and once per hour 
while the participant is asleep, over a 24 hour period. Ambulatory measures provide a superior 
predictive value for cardiovascular events compared to clinic BP measurements and have been 
used in dementia research [22]. To evaluate BP variability, we use 1) within-subject standard 
deviation of systolic readings, 2) the ratio between the variability and the mean of all systolic 
reads and 3) difference between maximum and minimum 24 hr systolic BP.  
Cerebrospinal Fluid (CSF) Collection 
A after an 8-hour overnight fast, CSF is acquired via LP the morning of the Baseline and Month 
8 visits.. CSF collection is completed according to guidelines put forth in the “Biospecimens 
Best Practice Guidelines for the ADCs” published by the National Alzheimer's Coordinating 
Center (NACC). Participants are placed in the sitting position and asked to maximally flex their 
knees, hips, back, and neck. The skin over L4-L5 is prepped and draped in a sterile manner. 1% 
lidocaine is used as a local anesthetic, followed by insertion of a spinal needle with introducer 
into the L4-L5 interspace using sterile technique. Using a 24 gauge Sprotte needle and a gentle 
extraction technique, approximately 22 ml of CSF is collected using sterile polypropylene 
collection tubes. Samples undergo a 10 minute 2500rpm spin and are aliquoted into 500µl 
polypropylene cryovials and stored at -80 for future assays, which will take place after all 
participants complete Baseline LP and bathed and tested again after all Month 8 CSF is 
collected.  
 CSF Biomarkers:   
  
 (i) RAS measures: To determine the extent to which telmisartan may penetrate the CNS, 
we will analyze key RAS components (such as ACE, angiotensin I, II, III, IV and ACE2) at 
Baseline and Month 8.We will use established methods including ELISA and activity assays 
using specific fluorogenic substrates [23-25] which, when coupled with the RAS measures 
collected in plasma, will provide the most comprehensive characterization of systemic and brain 
RAS function in African Americans to date. 
(ii) Tau and Abeta: CSF T-tau concentration is determined using a sandwich ELISA 
(Innotest hTAU-Ag, Innogenetics, Ghent, Belgium) specifically constructed to measure all tau 
isoforms irrespective of phosphorylation status [23]. Tau phosphorylated at threonine 181 (P-tau) 
was measured using a sandwich ELISA method (INNOTEST® PHOSPHO-TAU (181P), 
Innogenetics, Ghent, Belgium) [24]. Aβ1–42 levels will be determined using a sandwich ELISA 
(INNOTEST® β-AMYLOID(1–42), Innogenetics, Gent, Belgium), specifically constructed to 
measure Aβ containing both the first and 42nd amino acid [25]. Samples will be assayed in one 
batch after study completion by Dr. Zetterberg, an expert in CSF AD biomarkers. Dr. Zetterberg 
has performed all of our CSF biomarkers in this same ‘at risk’ cohort. All assays are performed 
as singlicates because the measurements are well standardized. Assay stability is monitored 
throughout the sample series using quality control samples representing low and high biomarker 
concentrations. Plates with CVs of the quality samples higher that 15% will be re-analyzed. All 
assays are conducted by board-certified laboratory technicians blinded to participant clinical 
characteristics and randomization group. 
 (iii) Immunophenotyping and Inflammatory Markers: These data will be used to test the 
hypothesis that RAS function is linked to peripheral and central inflammation as well as immune 
cell profile regulation. Inflammatory cell phenotyping will be performed via flow cytometry. We 
  
have successfully collected sufficient amounts of cells from CSF for analysis of immune cell 
subsets such as monocytes and other leukocytes. Assessment of cell-type specific markers allow 
quantification of monocyte, B-cell, and T-cell (CD4+ and CD8+) frequencies at Baseline. 
Additional markers of immune cell activation are obtained ex vivo in plated cells following 
incubation with various activating ligands and will allow sensitive detection of immune 
dysregulation. This novel method for CSF immunophenotyping provides invaluable information 
regarding the changes in immune cell frequency and their activation responses that occur in 
individuals at high risk for AD [26].  
 
Neuroimaging Participants undergo a one-hour MRI at Baseline and Month 8. Scan protocol 
includes structural MRI (e.g. T1-weighted imaging, Diffusion Tensor Imaging, T2 and 
T2FLAIR) and blood flow based measures (e.g. ASL perfusion, resting BOLD, and activation 
BOLD). MRI data will be acquired using a Siemens Tim Trio 3.0-Tesla scanner (Siemens Inc., 
Erlangen, Germany). The protocol included a 3D T1-weighted magnetization-prepared rapid 
acquisition with gradient echo (MPRAGE) anatomical imaging (TR/TI/TE = 2300/900/3.0ms, 
FA = 9°, voxel size = 1 x 1 x 1.2 mm3, 176 slices). Subcortical volumes were extracted using a 
user-independent parcellation process in Freesurfer (version 5.03, MGH, Charlestown, MA) 
running on a Centos 6.6 operating system. Technical details of this protocol have been described 
previously in detail [27]. As an overview, nonbrain tissues are removed and a Tailairach 
transform is applied. Subcortical white matter and deep gray matter structures are parcellated by 
combining data from voxel intensity, probabilistic atlas locations, and local relationships 
between anatomical structures. This information is used to automatically assign each voxel to a 
neuroanatomical label. A Bayesian model based on prior manual tracings is applied. Lesion 
  
segmentation tool (LST) will be used to segment and quantify volume of white matter hyper-
intensity 
Regions of Interest: Several of our analyses focus on specific brain regions of interest 
(ROIs) including regions that our preliminary studies indicate are affected preclinically. These 
include: 1) posterior cingulum bundle (PCB), 2) the portion of the cingulum bundle that runs 
between PCB and hippocampus, 3) retrosplenial white matter, 4) entorhinal white matter, 5) 
white matter adjacent to hippocampus, 6) fornix, and 7) splenium of the corpus callosum. 
Broader white matter analyses use voxel-wise methods, allowing us to test for effects in long 
(and late-myelinating) fiber bundles such the superior longitudinal fasciculus, which are known 
to be affected in AD. 
Blood Collection Participants undergo blood draw for (i) RAS function assessment including 
aldosterone, angiotensinogen, renin and ACE activity and levels; (ii) APOE genotyping; (iii) 
inflammatory markers in plasma (MSD V-PLEX Pro-inflammatory Panel 1); (iv) peripheral 
blood mononuclear cell (PBMC) immunophenotype. 
(i) RAS function:  We measure, using established methods [23, 25], RAS components that focus 
around the generation (ACE) and degradation (ACE2) of angiotensin II to determine the levels of 
RAS activity that is mediated through angiotensin II, the primary mediator of RAS.   
 (ii) ApoE Genotyping: Venous blood is collected into EDTA anticoagulated tubes and 
genomic DNA is isolated by standard protocols. We isolate 50 to 70g of DNA from 2 mL of 
whole blood. APOE genotypes are determined by real-time polymerase chain reaction using 
TaqMan probes (Applied Biosystems Inc.) unique for each APOE single-nucleotide 
  
polymorphism, rs429358 (assay ID C3084793 20) and rs7412 (assay ID C 904973 10), 
according to established protocols. 
 (iii & iv) Inflammation and Immunophenotyping: Using flow cytometry markers 
designed for the Human Immunophenotype Project (Stanford University), alterations of 
peripheral immune cell profiles in B cells (CD19), T cells (CD3, CD4, CD8), dendritic cells 
(CD11c, CD123), monocytes (CD14, CD16) and their activation status is assessed. Inducibility 
of MHC-II (HLA-DR and HLA- DQ) in monocytes treated with IFNγ is also assessed along with 
cytokine secretion in the conditioned media (MSD human V-PLEX Pro- inflammatory panel). 
We have previously reported an association between inflammation and cognitive performance in 
African Americans than Caucasians, and have recently reported higher levels of inflammation in 
both blood and CSF in a middle age cohort at risk for AD [26, 28]. 
Neuropsychological testing: Testing is being conducted to determine the potential impact of 
telmisartan vs. placebo on cognition over eight months. Neuropsychological testing lasts 
approximately one hour and includes both paper and pencil and computerized tasks. Alternative 
testing forms are not available for cognitive tests included in the present study, so the potential 
for practice effects may exist. Of all the cognitive domains, executive function is particularly 
vulnerable to vascular dysfunction and is impaired in early AD associated cognitive decline [29, 
30]. Executive function is assessed using the NINDS-initiated EXecutive Abilities: Measures and 
Instruments for Neurobehavioral Evaluation and Research or “EXAMINER” tool box. This test 
battery reliably and validly assesses executive function in clinical trials 
[http://examiner.ucsf.edu/] [31-33]. Additional tests include measures of overall cognitive status 
(MOCA; which is also given at Screening) [20], memory (Benson Figure [34], Buschke 
Selective Reminding Test [35]), attention / set shifting (Trails A & B [36], Digit Span) [37], 
  
visuospatial functioning (Mental Rotation Test (MRT)) [38], and language (Multilingual Naming 
Test (MINT)) [39]. 
Questionnaires: The following information is collected from participants at Baseline and Month 
8. Most questionnaires are computerized using the RedCap system and emailed to participants 
before their Baseline and Month 8 visits, so participants can complete them at their leisure and to 
cut down on study visit duration. Questionnaires include information pertaining to: (i) medical 
and medication history; (ii) exercise [40]; (iii) sleep [41]; (iv) nutrition [42]; (v) positive [43, 44] 
and negative (stress) aspects of caregiving [45-47]; (vi) depression [48]; and (vii) behavior and 
quality of life of their parent with AD [49, 50]. 
Adverse events (AE) and Data Safety and Monitoring: HEART is approved by the Emory 
University Institutional Review Board. Participants are screened for AEs via self-report at all 
visits. Questions and blood work regarding potential medication related symptoms include 
dizziness, light-headedness, weakness, lower extremity edema, hypotension, renal insufficiency, 
and hyperkalemia. Safety procedures are implemented in accordance with NIH safety policies 
for clinical trials. The safety monitoring is conducted by the PI the study physician, and a Data 
and Safety Monitoring Board (DSMB). The DSMB is comprised of 3 members including 2 
physicians familiar with RCTs and African American hypertension studies and an experienced 
biostatistician. 
 
Analyses and Power Calculations 
We will conduct Wilcoxon-Mann-Whitney tests to assess whether the change in the level of each 
CSF biomarker (Month 8 vs Baseline) differs between the treated group and placebo group. 
Tests will be conducted separately for each dose group (20 mg and 40 mg) but we will also 
  
consider testing for a dose-response by conducting Jonckheere-Terpstra trend tests. P-values < 
0.05 will be regarded as significant for the primary outcomes (CSF Aβ, tau, ACE). We will use 
False discovery Rate (FDR) correction to adjust p values for all secondary outcomes. We will 
use a 0.025 alpha level for all outcomes, which is in accordance with the FDR. We will consider 
linear regression analysis (outcome is 8-month change in a biomarker) to adjust for demographic 
or clinical confounders. Demographic covariates will include age, education and gender. Clinical 
covariates will correspond to the appropriate outcomes, and will include, but are not limited to, 
ApoE 4 status, blood pressure, and depression. Power calculations for ACE, CBF, Aβ and tau 
comparisons are based on data from previous trials in similar populations. With 20 participants 
per group, we will have 99% power to detect change in ACE levels and 80% power to detect 
differences in CSF Aβ, tau and CBF between the treated groups and placebo (based on 2-sided 




With the increasing incidence and prevalence of AD, research efforts should target high-risk 
groups in order to prevent or slow disease progression in tandem with cure-driven research 
directives in established disease. Repurposing existing medications that have been shown to be 
beneficial in observational and clinical trials is a cost effective way of slowing AD, particularly 
in high-risk individuals, and allow for more rapid research trajectories over conventional drug 
discovery approaches [51]. While longer interventions are optimal in healthy controls, early 
intervention is critical and assessing the impact on biomarkers in addition to cognitive changes is 
also of great importance. Because we know that the brain RAS is implicated in AD 
  
neuropathology in Caucasians, research should clinically investigate the extent to which RAS 
medications confer AD-related benefits in African Americans via the same mechanism, and the 
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